Absci Corp. (ABSI) fundamentals score
Absci is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Its integrated drug creation platform combines Origin-1, its generative design model, with rapid validation using its lab-in-the-loop.
Services-Commercial Physical & Biological Research · Industrials · Listed on NASDAQ
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 2.9/10
- Profitability: 1.0/10
- Financial health: 6.6/10
- Earnings quality: 7.0/10
- Valuation: 1.5/10
Scores are calculated from Absci Corp.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Industrials stocks
- Sezzle Inc. (SEZL): 9.1/10
- Paymentus Holdings, Inc. (PAY): 8.7/10
- Argan Inc. (AGX): 8.6/10
- Ferguson Enterprises Inc. (FERG): 8.6/10
- International Seaways, Inc. (INSW): 8.6/10
- Dorian Lpg Ltd. (LPG): 8.6/10
- Quinstreet, Inc. (QNST): 8.6/10
- Remitly Global, Inc. (RELY): 8.6/10